We would like to inform you that, based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company has approved and passed the resolutions by circulation on April 03, 2026 as enclosed.
BLISSGVS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Bliss GVS Pharma Limited's Board of Directors passed a circular resolution on April 3, 2026, appointing two Additional Directors as Non-Executive Independent Directors for 5-year terms. Mr. Vijayanarayanan Mahadevan, a Chartered Accountant with 35+ years in finance leadership at companies like Novartis and Alcon, was appointed. Mr. Deepak Rameshchandra Shah, a Fellow CA with 36+ years in taxation and audit, who served as President of the Bombay Chartered Accountants' Society, was also appointed. Both appointments are subject to shareholder approval via postal ballot. Neither director is related to any existing board members or promoters, and both are not debarred from holding director positions.
The appointments strengthen the Board's independence and expertise in finance and taxation, which is positive for corporate governance. Shareholders will vote on these appointments, and no immediate stock impact is expected as these are routine governance changes.